Optimization of dosing regimens of vancomycin, teicoplanin, linezolid and daptomycin against methicillin-resistant Staphylococcus aureus in neutropenic patients with cancer by Monte Carlo simulations. (24th November 2021)

• Record Type: Journal Article
• Authors: Wei, Xiaochen; Zhao, Mingfeng; Xiao, Xia
• Is Part Of: Journal of chemotherapy. Volume 32:Number 8(2020)
• Page Start: 547
• Page End: 553
• Publication Date: 2021-11-24
• Subjects: Vancomycin -- teicoplanin -- linezolid -- daptomycin -- methicillin-resistant Staphylococcus aureus -- neutropenia -- cancer -- pharmacokinetic/pharmacodynamic; Chemotherapy -- Periodicals; Drug Therapy -- Periodicals; 615.58
• DOI: 10.1080/1120009X.2021.1931758
• Languages: English
• ISSNs: 1120-009X

Abstract

Abstract : The objective of this study was to evaluate the efficacy of various dosing regimens of vancomycin, teicoplanin, linezolid and daptomycin against methicillin-resistant Staphylococcus aureus (MRSA) in neutropenic patients with cancer. Monte Carlo simulations were conducted using pharmacokinetic parameters and pharmacodynamic data to determine cumulative fraction of response (CFRs) in terms of area under the concentration-time curve/minimum inhibition concentration target. Currently clinical standard dosing regimens of vancomycin, teicoplanin, linezolid and daptomycin were insufficient to provide expected CFRs against MRSA for neutropenic patients with cancer. The high dosing regimens of vancomycin (3500 mg/d), teicoplanin (800 mg/d) and daptomycin (8 mg/kg/d) could provide CFRs of ≥ 80%, showing a higher treatment success. However, the majority of CFRs with linezolid simulated dosing regimens reached < 80% against MRSA. Therefore, a strategy of high dosages of vancomycin, teicoplanin and daptomycin may be needed to attain optimal therapeutic efficacy against MRSA in neutropenic patients with cancer.